Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 1, 2016, Pages 18-29

  Kumar, Riten ^a   Dunn, Amy ^a   Carcao, Manuel ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

gene therapy; hemophilia; prophylaxis

Indexed keywords

ALBUMIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ACE910; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR;

ADENO ASSOCIATED VIRUS; ARTICLE; DISEASE SEVERITY; DRUG HALF LIFE; GENE THERAPY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LIFE EXPECTANCY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; BLOOD; COMPLICATION; HALF LIFE TIME; PROCEDURES; TRENDS;

BLOOD COAGULATION FACTORS; GENETIC THERAPY; HALF-LIFE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; QUALITY OF LIFE;

EID: 84954488034     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1568877     Document Type: Article

References (113)

1. Stonebraker J. S., Bolton-Maggs P. H., Michael Soucie J., Walker I., Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia: 2012; 18 3 e91 e94
2. Stonebraker J. S., Bolton-Maggs P. H., Soucie J. M., Walker I., Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia: 2010; 16 1 20 32
3. Kumar R., Carcao M. Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond. Pediatr Clin North Am: 2013; 60 6 1419 1441
4. Berntorp E., Shapiro A. D. Modern haemophilia care. Lancet: 2012; 379 9824 1447 1456
5. Berntorp E. History of prophylaxis. Haemophilia: 2013; 19 2 163 165
6. Ljung R., Gretenkort Andersson N. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol: 2015; 169 6 777 786
7. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl: 1965; 77 3 132
8. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand: 1962; 171 237 242
9. Manco-Johnson M. J., Abshire T. C., Shapiro A. D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med: 2007; 357 6 535 544
10. Franchini M., Mannucci P. M. The history of hemophilia. Semin Thromb Hemost: 2014; 40 5 571 576
11. Schramm W. The history of haemophilia - a short review. Thromb Res: 2014; 134 01 S4 S9
12. Otto J. C. An account of an hemorrhagic disposition existing in certain families. Clin Orthop Relat Res: 1996; 328 4 6
13. Mannucci P. M., Tuddenham E. G. The hemophilias - from royal genes to gene therapy. N Engl J Med: 2001; 344 23 1773 1779
14. Stevens R. F. The history of haemophilia in the royal families of Europe. Br J Haematol: 1999; 105 1 25 32
15. Rogaev E. I., Grigorenko A. P., Faskhutdinova G., Kittler E. L., Moliaka Y. K. Genotype analysis identifies the cause of the royal disease. Science: 2009; 326 5954 817
16. Patek A. J., Taylor F. H. Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest: 1937; 16 1 113 124
17. Biggs R., Douglas A. S., MacFarlane R. G., Dacie J. V., Pitney W. R., Merskey. Christmas disease: a condition previously mistaken for haemophilia. Br Med J: 1952; 2 4799 1378 1382
18. Biggs R. Thirty years of haemophilia treatment in Oxford. Br J Haematol: 1967; 13 4 452 463
19. Pool J. G., Gershgold E. J., Pappenhagen A. R. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature: 1964; 203 312
20. Mannucci P. M. Hemophilia and related bleeding disorders: a story of dismay and success. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program: 2002; 1 9
21. Baxter T., Black D., Birks D. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Lancet: 1998; 351 9102 600 601
22. White G. C. II, McMillan C. W., Kingdon H. S., Shoemaker C. B. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med: 1989; 320 3 166 170
23. Nilsson I. M., Hedner U., Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand: 1976; 65 2 129 135
24. Nilsson I. M., Berntorp E., Löfqvist T., Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med: 1992; 232 1 25 32
25. Astermark J., Petrini P., Tengborn L., Schulman S., Ljung R., Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol: 1999; 105 4 1109 1113
26. Fischer K., van der Bom J. G., Mauser-Bunschoten E. P., et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood: 2002; 99 7 2337 2341
27. Gringeri A., Lundin B., von Mackensen S., Mantovani L., Mannucci P. M.; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost: 2011; 9 4 700 710
28. Kreuz W., Escuriola-Ettingshausen C., Funk M., Schmidt H., Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? - The German experience. Haemophilia: 1998; 4 4 413 417
29. Berntorp E., Boulyjenkov V., Brettler D., et al. Modern treatment of haemophilia. Bull World Health Organ: 1995; 73 5 691 701
30. Richards M., Williams M., Chalmers E., et al. Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol: 2010; 149 4 498 507
31. Blanchette V. S., Key N. S., Ljung L. R., Manco-Johnson M. J., van den Berg H. M., Srivastava A.; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost: 2014; 12 11 1935 1939
32. Berntorp E., Halimeh S., Gringeri A., Mathias M., Escuriola C., Pérez R. Management of bleeding disorders in children. Haemophilia: 2012; 18 02 15 23
33. Valentino L. A., Kawji M., Grygotis M. Venous access in the management of hemophilia. Blood Rev: 2011; 25 1 11 15
34. Feldman B. M., Pai M., Rivard G. E., et al. Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost: 2006; 4 6 1228 1236
35. Hilliard P., Zourikian N., Blanchette V., et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost: 2013; 11 3 460 466
36. Kraft J., Blanchette V., Babyn P., et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost: 2012; 10 12 2494 2502
37. van Dijk K., Fischer K., van der Bom J. G., Scheibel E., Ingerslev J., van den Berg H. M. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol: 2005; 130 1 107 112
38. Collins P., Faradji A., Morfini M., Enriquez M. M., Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost: 2010; 8 1 83 89
39. Manco-Johnson M. J., Sanders J., Ewing N., Rodriguez N., Tarantino M., Humphries T.; TEEN/TWEN Study Group. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia: 2013; 19 5 727 735
40. Manco-Johnson M. J., Kempton C. L., Reding M. T., et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost: 2013; 11 6 1119 1127
41. Carcao M. Switching from current factor VIII (FVIII) to longer acting FVIII concentrates--what is the real potential benefit? Haemophilia: 2015; 21 3 297 299
42. Blanchette V. S., McCready M., Achonu C., Abdolell M., Rivard G., Manco-Johnson M. J. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia: 2003; 9 01 19 26, discussion 26
43. Duncan N., Shapiro A., Ye X., Epstein J., Luo M. P. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia: 2012; 18 5 760 765
44. Thornburg C. D., Carpenter S., Zappa S., Munn J., Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Haemophilia: 2012; 18 4 568 574
45. Hacker M. R., Geraghty S., Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia: 2001; 7 4 392 396
46. Mahdi A. J., Obaji S. G., Collins P. W. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol: 2015; 169 6 768 776
47. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia: 2014; 20 04 99 105
48. Shapiro A. D., Ragni M. V., Kulkarni R., et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost: 2014; 12 11 1788 1800
49. Lencer W. I., Blumberg R. S. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol: 2005; 15 1 5 9
50. Shapiro A. D., Ragni M. V., Valentino L. A., et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood: 2012; 119 3 666 672
51. Powell J. S., Pasi K. J., Ragni M. V., et al. B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med: 2013; 369 24 2313 2323
52. Powell J., Shapiro A., Ragni M., et al. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol: 2015; 168 1 113 123
53. Powell J. S., Apte S., Chambost H., et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol: 2015; 168 1 124 134
54. Fischer K., Kulkarni R., Bradbury M., et al. Pharmacokinetics of recombinant factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B: an interim analysis of the Kids B-LONG Study. Blood: 2013; 122 21
55. Fischer K., Kulkarni R., Nolan B., et al. Safety, efficacy and pharmacokinetics of recombinant factor IX FC fusion protein in children with haemophilia B (KIDS B-LONG). J Thromb Haemost: 2015; 13 87 87
56. Negrier C., Knobe K., Tiede A., Giangrande P., Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood: 2011; 118 10 2695 2701
57. Collins P. W., Young G., Knobe K., et al. paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood: 2014; 124 26 3880 3886
58. Carcao M., Zak M., Karim F. A., et al. Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously treated pediatric hemophilia B patients. Blood: 2014; 124 21
59. Metzner H. J., Weimer T., Kronthaler U., Lang W., Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost: 2009; 102 4 634 644
60. Santagostino E., Negrier C., Klamroth R., et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood: 2012; 120 12 2405 2411
61. Martinowitz U., Lissitchkov T., Lubetsky A., et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia: 2015; 21 6 784 790. doi:10.1111/hae.12721
62. Santagostino E., Jacobs I. C., Voigt C., Feussner A., Limsakun T. Pharmacokinetic results of two phase III clinical studies of coagulation factor ix (recombinant) albumin fusion protein (rIX-FP) in previously treated patients with hemophilia B (PROLONG-9FP). Blood: 2014; 124 21
63. Powell J. S., Josephson N. C., Quon D., et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood: 2012; 119 13 3031 3037
64. Mahlangu J., Powell J. S., Ragni M. V., et al. A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood: 2014; 123 3 317 325
65. Young G., Mahlangu J., Kulkarni R., et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost: 2015; 13 6 967 977
66. Tiede A., Brand B., Fischer R., et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost: 2013; 11 4 670 678
67. Giangrande P., Chowdary P., Enhrenforth S., et al. Clinical evaluation of novel recombinant glycopegylated FVIII (turoctocog alfa pegol, N8-GP): efficacy and safety in previously treated patients with severe hemophilia A--results of pathfinder (TM) 2 international trial. J Thromb Haemost: 2015; 13 176 176
68. Coyle T. E., Reding M. T., Lin J. C., Michaels L. A., Shah A., Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost: 2014; 12 4 488 496
69. Boggio L. N., Hong W., Wang M., Eyster M. E., Michaels L. A. Bleeding Phenotype with Various Bay 94-9027 Dosing Regimens: Subanalyses from the Protect VIII Study. Blood: 2014; 124 21
70. Turecek P. L., Bossard M. J., Graninger M., et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie: 2012; 32 01 S29 S38
71. Konkle B. A., Stasyshyn O., Chowdary P., et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood: 2015; 126 9 1078 1085
72. Schmidbauer S., Witzel R., Robbel L., et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res: 2015; 136 2 388 395
73. Mahlangu J., Kuliczkowski K., Stasyshyn O., et al. RVIII-SingleChain, results of the pivotal phase I/III PK, efficacy and safety clinical trial in adults and adolescents with severe hemophilia A. J Thromb Haemost: 2015; 13 86 86
74. Khayat C. D., Mahlangu J., Leisinger C., et al. Efficacy and safety of RVIII-SingleChain in surgical prophylaxis. J Thromb Haemost: 2015; 13 602 602
75. Lheriteau E., Davidoff A. M., Nathwani A. C. Haemophilia gene therapy: progress and challenges. Blood Rev: 2015; 29 5 321 328
76. Knobe K., Berntorp E. New treatments in hemophilia: insights for the clinician. Ther Adv Hematol: 2012; 3 3 165 175
77. Giles A. R., Tinlin S., Hoogendoorn H., Greenwood P., Greenwood R. Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency). Blood: 1984; 63 2 451 456
78. Wang L., Zoppè M., Hackeng T. M., Griffin J. H., Lee K. F., Verma I. M. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A: 1997; 94 21 11563 11566
79. Armstrong E. P., Malone D. C., Krishnan S., Wessler M. J. Costs and utilization of hemophilia A and B patients with and without inhibitors. J Med Econ: 2014; 17 11 798 802
80. Chuah M. K., Evens H., VandenDriessche T. Gene therapy for hemophilia. J Thromb Haemost: 2013; 11 01 99 110
81. McIntosh J., Lenting P. J., Rosales C., et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood: 2013; 121 17 3335 3344
82. Nathwani A. C., Nienhuis A. W., Davidoff A. M. Our journey to successful gene therapy for hemophilia B. Hum Gene Ther: 2014; 25 11 923 926
83. Nathwani A. C., Reiss U. M., Tuddenham E. GD., et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med: 2014; 371 21 1994 2004
84. Nathwani A. C., Tuddenham E. GD, Rangarajan S., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med: 2011; 365 25 2357 2365
85. Powell J. S., Ragni M. V., White G. C. II., et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood: 2003; 102 6 2038 2045
86. Qiu X., Lu D., Zhou J., et al. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients. Chin Med J (Engl): 1996; 109 11 832 839
87. Roth D. A., Tawa N. E. Jr, O'Brien J. M., Treco D. A., Selden R. F.; Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med: 2001; 344 23 1735 1742
88. Roth D. A., Tawa N. E., Proper J., et al. Implantation of non-viral ex vivo genetically modified autologous dermal fibroblasts that express B-domain deleted human factor VIII in 12 severe hemophilia A study subjects. Blood: 2002; 100 11 116a 117a
89. Gansbacher B.; European Society of Gene Therapy; Position of the European Society of Gene Therapy (ESGT). Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). J Gene Med: 2003; 5 3 261 262
90. Hacein-Bey-Abina S., von Kalle C., Schmidt M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med: 2003; 348 3 255 256
91. Ohmori T., Mizukami H., Ozawa K., Sakata Y., Nishimura S. New approaches to gene and cell therapy for hemophilia. J Thromb Haemost: 2015; 13 01 S133 S142
92. Kay M. A., Manno C. S., Ragni M. V., et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet: 2000; 24 3 257 261
93. Manno C. S., Chew A. J., Hutchison S., et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood: 2003; 101 8 2963 2972
94. High K. A., Manno C. S., Sabatino D. E., et al. Immune responses to AAV and to factor IX in a phase I study of AAV-mediated, liver-directed gene transfer for hemophilia B. Blood: 2003; 102 11 154a 155a
95. Davidoff A. M., Ng C. YC, Zhou J. F., Spence Y., Nathwani A. C. Administration of adenovirus months after transduction of the liver by recombinant adeno-associated virus (rAAV) significantly enhances stable rAAV transgene expression by mechanism independent of second strand synthesis. Mol Ther: 2003; 7 5 S45 S45
96. Gao G. P., Alvira M. R., Wang L., Calcedo R., Johnston J., Wilson J. M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A: 2002; 99 18 11854 11859
97. Grimm D., Zhou S., Nakai H., et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood: 2003; 102 7 2412 2419
98. High K. H., Nathwani A., Spencer T., Lillicrap D. Current status of haemophilia gene therapy. Haemophilia: 2014; 20 04 43 49
99. Mimuro J., Mizukami H., Shima M., et al. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol: 2014; 86 11 1990 1997
100. Oldenburg J., Albert T. Novel products for haemostasis - current status. Haemophilia: 2014; 20 04 23 28
101. Powell J. S. Lasting power of new clotting proteins. Hematology Am Soc Hematol Educ Program: 2014; 2014 1 355 363
102. Kitazawa T., Igawa T., Sampei Z., et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med: 2012; 18 10 1570 1574
103. Lillicrap D. A complex substitute: antibody therapy for hemophilia. Nat Med: 2012; 18 10 1460 1461
104. Muto A., Yoshihashi K., Takeda M., et al. Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost: 2014; 12 2 206 213
105. Shima M. The potential of bispecific antibodies for treatment of hemophilia A. J Thromb Haemost: 2015; 13 5 6
106. Shima M., Hanabusa H., Taki M., et al. Long-term safety and prophylactic efficacy of once-weekly subcutaneous administration of ACE910, in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study. J Thromb Haemost: 2015; 13 6 7
107. Hilden I., Lauritzen B., Sorensen B. B., et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood: 2012; 119 24 5871 5878
108. Petersen L. C. Hemostatic properties of a TFPI antibody. Thromb Res: 2012; 129 02 S44 S45
109. Gissel M., Orfeo T., Foley J. H., Butenas S. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res: 2012; 130 6 948 955
110. Gu J. M., Ho E., Zhao X. Y., et al. Pharmacodynamics and pharmacokinetics of TFPI-neutralizing antibody (BAY1093884) in cynomolgus monkeys and prediction of human dose. J Thromb Haemost: 2015; 13 7 7
111. Waters E. K., Sigh J., Ezban M., Hilden I. Thrombin generation is increased in plasma from healthy males who have received concizumab, an antibody against tissue factor pathway inhibitor (ExplorerTM2). J Thromb Haemost: 2015; 13 7 7
112. Kumar R., Chan A. KC, Dawson J. E., Forman-Kay J. D., Kahr W. H., Williams S. Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. Br J Haematol: 2014; 166 1 130 139
113. Sehgal A., Barros S., Ivanciu L., et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med: 2015; 21 5 492 497